Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Specialised Therapeutics gets exclusive Asian rights to Puma's Nerlynx

Executive Summary

Puma Biotechnology Inc. granted Specialised Therapeutics Asia Pte. Ltd. exclusive rights to sell the breast cancer therapy Nerlynx (neratinib) in Southeast Asia, including Australia, Singapore, Malaysia, Brunei, and New Zealand.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register